Previous 10 | Next 10 |
– Teijin to receive exclusive license to further develop and commercialize TransCon™ hGH, TransCon™ PTH, and TransCon™ CNP in Japan – Ascendis Pharma is eligible to receive $70 million upfront, development/regulatory milesto...
2023-11-28 12:33:17 ET Summary Ascendis Pharma A/S reported strong sequential growth of Skytrofa and raised its full-year net sales guidance range. The NDA resubmission for TransCon PTH is expected by mid-November, with FDA feedback by mid-December and a potential PDUFA date in Ja...
2023-11-22 14:15:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2023-11-21 09:32:26 ET More on Ascendis Pharma Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript Citi opens 30-day catalyst watch ...
- YORVIPATH (developed as TransCon PTH) is a parathyroid hormone (PTH) replacement therapy indicated for the treatment of adults with chronic hypoparathyroidism - Ascendis plans its first EU launch of YORVIPATH in Germany in January 2024 COPENHAGEN, Denmark, Nov. 20, 2023 (GLO...
2023-11-16 13:52:08 ET More on Ascendis Pharma Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript Ascendis resubmits FDA applicatio...
2023-11-15 12:36:58 ET More on Ascendis Pharma Ascendis Pharma A/S (ASND) Q3 2023 Earnings Call Transcript Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript Ascendis Pharma Q3 2023 Earnings ...
COPENHAGEN, Denmark, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that it has resubmitted its New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for the treatment of adults with hypoparathyroidism to the U.S. Food & Drug Administration (F...
2023-11-07 20:22:08 ET Ascendis Pharma A/S (ASND) Q3 2023 Results Conference Call November 07, 2023 04:30 PM ET Company Participants Timothy Lee - Investor Relations Jan Mikkelsen - President and Chief Executive Officer Scott Smith - Executive Vice President and ...
2023-11-07 16:24:00 ET More on Ascendis Pharma Ascendis Pharma: Revenue Promise Meets Cash Flow Challenge Ascendis Pharma A/S (ASND) Q2 2023 Earnings Call Transcript Ascendis Pharma Q3 2023 Earnings Preview EMA advisors recommend many new meds at latest meeti...
News, Short Squeeze, Breakout and More Instantly...
Pendopharm signs exclusive distribution agreement with Ascendis Pharma A/S for TransCon™ PTH in Canada Canada NewsWire MONTREAL , July 4, 2024 /CNW/ - Pendopharm, a division of Pharmascience Inc., announced today that it has signed an exclusive distributio...
• Data demonstrate significant improvements in well-being and physical functioning compared to placebo in patients treated for 1 year with TransCon CNP at the pivotal 100μg/kg/week dose • Improvements could not be explained by changes in linear growth only, supporti...
2024-06-19 21:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...